Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 5/2019

Open Access 01-05-2019 | NSCLC | Original Article

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC

Authors: Shunichi Sugawara, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Hiroshi Nokihara, Yuichiro Ohe, Makoto Nishio, Toshiaki Takahashi, Koichi Goto, Makoto Maemondo, Yukito Ichinose, Takashi Seto, Hiroshi Sakai, Akihiko Gemma, Fumio Imamura, Masato Shingyoji, Hideo Saka, Akira Inoue, Koji Takeda, Isamu Okamoto, Katsuyuki Kiura, Satoshi Morita, Tomohide Tamura

Published in: International Journal of Clinical Oncology | Issue 5/2019

Login to get access

Abstract

Introduction

The East Asia S-1 Trial in Lung Cancer (EAST-LC) was a randomized phase III study conducted in East Asia that demonstrated the non-inferiority of S-1 to docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). Here, we reported the results of the Japanese subgroup treated with docetaxel 60 mg/m2, the standard dosage in Japan.

Patients and methods

Patients were randomized 1:1 to receive either S-1 or docetaxel. The primary endpoint was overall survival (OS); the secondary endpoints included progression-free survival (PFS), response rate (RR), quality of life (QOL), and safety.

Results

Patient characteristics in the Japanese subgroup (n = 724) were similar to those in the overall EAST-LC population. Median OS was 13.4 months in the S-1 group and 12.6 months in the docetaxel group. In pemetrexed-pretreated patients, OS with S-1 was similar to that with docetaxel. Median PFS was 2.9 and 3.0 months in the S-1 and docetaxel groups, respectively. RR was 9.4% and 10.3% in the S-1 and docetaxel groups, respectively. The QOL of patients treated with S-1 was better compared with that of patients treated with docetaxel. Decreased appetite and diarrhea were more common in the S-1 group, whereas the frequency of neutropenia and febrile neutropenia was markedly higher in the docetaxel group.

Conclusions

This Japanese subgroup analysis showed that S-1 had similar efficacy to docetaxel in patients with previously treated advanced NSCLC. These results are similar to those of the overall EAST-LC population.
Appendix
Available only for authorised users
Literature
1.
2.
Dela Cruz CS, Tanoue LT, Matthay RA (2011) Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 32:605–644CrossRefPubMed
3.
Favaretto A, Pasello G, Magro C et al (2009) Second and third line treatment in non-small cell lung cancer. Crit Rev Oncol Hematol 71:117–126CrossRefPubMed
4.
Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289CrossRefPubMed
5.
Hanna N, Johnson D, Temin S et al (2017) Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3484–3515CrossRefPubMed
6.
Novello S, Barlesi F, Califano R et al (2016) Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v1–v27CrossRefPubMed
7.
8.
Wang F, Mishina S, Takai S et al (2017) Systemic treatment patterns with advanced or recurrent non-small cell lung cancer in Japan: a retrospective hospital administrative database study. Clin Ther 39:1146–1160CrossRefPubMed
9.
Schöffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15:85–106CrossRefPubMed
10.
Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548–557CrossRefPubMed
11.
Okamoto I, Yoshioka H, Morita S et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a West Japan Oncology Group study. J Clin Oncol 28:5240–5246CrossRefPubMed
12.
Kubota K, Sakai H, Katakami N et al (2015) A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial. Ann Oncol 26:1401–1408CrossRefPubMedPubMedCentral
13.
Nokihara H, Nagai S, Kato T et al (2007) A phase II study of S-1 in non-small cell lung cancer (NSCLC) patients previously treated with a platinum-based regimen. J Thorac Oncol 2(suppl 4): S687CrossRef
14.
Totani Y, Saito Y, Hayashi M et al (2009) A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 64:1181–1185CrossRefPubMed
15.
Nokihara H, Lu S, Mok TSK et al (2017) Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). Ann Oncol 28:2698–2706CrossRefPubMedPubMedCentral
16.
Taguchi T, Furue H, Niitani H et al (1994) Phase I clinical trial of RP 56976 (docetaxel), a new anticancer drug. Gan To Kagaku Ryoho 21:1997–2005 (in Japanese) PubMed
17.
Kunitoh H, Watanabe K, Onoshi T et al (1996) Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 14:1649–1655CrossRefPubMed
18.
Mukohara T, Takeda K, Miyazaki M et al (2001) Japanese experience with second-line chemotherapy with low-dose (60 mg/m2) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 48:356–360CrossRefPubMed
19.
Takeda K, Negoro S, Tamura T et al (2009) Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncolgy Group trial (JCOG0104). Ann Oncol 20:835–841CrossRefPubMed
20.
Kawaguchi T, Ando M, Asami K et al (2014) Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 32:1902–1908CrossRefPubMed
21.
Yoshioka H, Katakami N, Okamoto H et al (2017) A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. Ann Oncol 28:285–291PubMed
22.
Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103CrossRefPubMed
23.
Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354–2362CrossRefPubMed
24.
Cocks K, King MT, Velikova G et al (2011) Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29:89–96CrossRefPubMed
25.
Kawaishi M, Wakui H, Yoshii Y et al (2013) Clinical outcome after S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed. Eur Respir J 42(suppl 57):P4485 (abstract:4803)
26.
Nakahara Y, Takagi Y, Nagamata M et al. (2015) Activity of S-1 for non-small cell lung cancer pretreated with pemetrexed. Ann Oncol 26(suppl 9):ix132 (abstract 437P)
27.
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentral
28.
29.
Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673CrossRefPubMed
30.
Reck M, Kaiser R, Mellemgaard A et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol 15:143–155CrossRefPubMed
Metadata
Title
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC
Authors
Shunichi Sugawara
Kazuhiko Nakagawa
Nobuyuki Yamamoto
Hiroshi Nokihara
Yuichiro Ohe
Makoto Nishio
Toshiaki Takahashi
Koichi Goto
Makoto Maemondo
Yukito Ichinose
Takashi Seto
Hiroshi Sakai
Akihiko Gemma
Fumio Imamura
Masato Shingyoji
Hideo Saka
Akira Inoue
Koji Takeda
Isamu Okamoto
Katsuyuki Kiura
Satoshi Morita
Tomohide Tamura
Publication date
01-05-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 5/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01396-z

Other articles of this Issue 5/2019

International Journal of Clinical Oncology 5/2019 Go to the issue

Correction

Correction to: Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

Original Article

Risk factors for cardiovascular mortality in patients with colorectal cancer: a population-based study

Original Article

Castration-resistant prostate cancer patients who had poor response on first androgen deprivation therapy would obtain certain clinical benefit from early docetaxel administration

Original Article

Interaction of H. pylori with toll-like receptor 2-196 to -174 ins/del polymorphism is associated with gastric cancer susceptibility in southern China

Original Article

Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin

Original Article

Optimal maximum duration for delaying salvage operation when recurrence of retroperitoneal liposarcoma is suspected: a single-center study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits